Guyasuta Investment Advisors Inc. Sells 5,355 Shares of Becton, Dickinson and Company $BDX

Key Points

• Guyasuta Investment Advisors Inc. sold 5,355 shares of Becton, Dickinson and Company, reducing its stake by 2.9%, and now owns 180,027 shares valued at approximately $31 million.
• Becton, Dickinson and Company reported a 10.4% year-over-year increase in revenue, reaching $5.51 billion, and its earnings per share surpassed analysts' expectations at $3.68.
• The company announced a quarterly dividend of $1.04 per share, reflecting an annual yield of 2.3%, with a payout ratio of 74.82%.

Guyasuta Investment Advisors Inc. lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 2.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 180,027 shares of the medical instruments supplier's stock after selling 5,355 shares during the quarter. Becton, Dickinson and Company comprises 1.9% of Guyasuta Investment Advisors Inc.'s portfolio, making the stock its 14th largest holding. Guyasuta Investment Advisors Inc. owned approximately 0.06% of Becton, Dickinson and Company worth $31,010,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Avior Wealth Management LLC boosted its position in shares of Becton, Dickinson and Company by 2,934.1% in the second quarter. Avior Wealth Management LLC now owns 7,919 shares of the medical instruments supplier's stock valued at $1,364,000 after acquiring an additional 7,658 shares during the period. RBA Wealth Management LLC boosted its position in shares of Becton, Dickinson and Company by 5.3% in the second quarter. RBA Wealth Management LLC now owns 23,115 shares of the medical instruments supplier's stock valued at $3,982,000 after acquiring an additional 1,163 shares during the period. Blossom Wealth Management boosted its position in shares of Becton, Dickinson and Company by 6.5% in the second quarter. Blossom Wealth Management now owns 1,498 shares of the medical instruments supplier's stock valued at $258,000 after acquiring an additional 92 shares during the period. TOWER TRUST & INVESTMENT Co boosted its position in shares of Becton, Dickinson and Company by 8.4% in the second quarter. TOWER TRUST & INVESTMENT Co now owns 1,852 shares of the medical instruments supplier's stock valued at $319,000 after acquiring an additional 143 shares during the period. Finally, Brown Lisle Cummings Inc. boosted its position in shares of Becton, Dickinson and Company by 30.6% in the second quarter. Brown Lisle Cummings Inc. now owns 917 shares of the medical instruments supplier's stock valued at $158,000 after acquiring an additional 215 shares during the period. 86.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research reports. Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a research report on Thursday. They issued a "sector perform" rating and a $211.00 price objective for the company. Argus increased their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Barclays cut their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Wells Fargo & Company upped their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Finally, Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $213.09.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Claire Fraser sold 917 shares of the firm's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,965 shares of company stock valued at $551,536 over the last quarter. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $184.59 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The stock has a fifty day moving average price of $188.27 and a two-hundred day moving average price of $188.72. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The firm has a market capitalization of $52.91 billion, a P/E ratio of 33.20, a P/E/G ratio of 1.49 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same period in the prior year, the company posted $3.50 earnings per share. The business's revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.3%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.